Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis

NCT05437263 is registered in ClinicalTrials.gov with Priovant Therapeutics, Inc. as lead sponsor.

NCT NCT05437263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05437263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis
Lead sponsor
Priovant Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2022
Completion date
September 9, 2026
Enrollment
241 (actual)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

dermatomyositis